Smailova Dariga S, Fabbro Elisa, Ibrayev Serik E, Brusati Luca, Semenova Yuliya M, Samarova Umutzhan S, Rakhimzhanova Farida S, Zhussupov Sabit M, Khismetova Zaituna A, Hosseini Hengameh
Semey Medical University, Semey, Kazakhstan.
Department of Medicine, Udine University, Udine, Italy.
Prostate Cancer. 2020 Jan 27;2020:6140623. doi: 10.1155/2020/6140623. eCollection 2020.
Prostate cancer (PCa) is the second most commonly diagnosed cancer, and the sixth most common killer among men worldwide (Aubry et al., 2013). This research was motivated by the fact that PCa screening continues to be a controversial topic in the Kazakh medical community. This study aimed at description of how newly diagnosed PCa patients are managed in Pavlodar region of the Kazakhstan Republic and at presentation of a budget impact analysis (BIA) for PCa screening program. Also, we aimed to provide a comparative analysis of pricing system on medical services applied in both private and public healthcare sectors of the Kazakhstan Republic. . New cases of PCa have been retrospectively analyzed for the period from January 2013 to December 2017 based on the information obtained from information system "Policlinic" maintained by the Pavlodar regional branch of the Republican Center for Electronic Health and from Cancer Registry of Pavlodar Regional Oncology Center. All data were analyzed with the help of SPSS 20.0 software. The mean age of PCa patients was 68.34 years (SD = 8.559). The government of Kazakhstan invested 20,437,000 KZT (Kazakhstani tenge) in 2017 equivalently 61,188 USD-to fund a pilot study for examination of 9638 men. From 2013 to 2017, out of 49,334 men residing in Pavlodar region of Kazakhstan 1,248 men were diagnosed with prostate diseases, including 130 PCa cases. The PCa detection rate was equal to two cases per month. Only 22.8% of all PCa cases identified in the region within specified time period were revealed as a result of the government-funded PCa screening program. The average prostate cancer detection rate among the target group of Pavlodar region within the period of 5 years was equal to 0.23%. Based on the fact that the PCa screening program failed to enable adequate detection of new PCa cases, we would not recommend to continue this type of screening unless it is undergone careful revision and replanning.
前列腺癌(PCa)是全球男性中第二大最常被诊断出的癌症,也是第六大常见死因(奥布里等人,2013年)。本研究的动机是,在哈萨克斯坦医学界,前列腺癌筛查仍然是一个有争议的话题。本研究旨在描述哈萨克斯坦共和国巴甫洛达尔地区新诊断出的前列腺癌患者的管理方式,并展示前列腺癌筛查项目的预算影响分析(BIA)。此外,我们旨在对哈萨克斯坦共和国私立和公共医疗部门应用的医疗服务定价系统进行比较分析。根据从哈萨克斯坦共和国电子健康共和中心巴甫洛达尔地区分支机构维护的“门诊”信息系统以及巴甫洛达尔地区肿瘤中心癌症登记处获得的信息,对2013年1月至2017年12月期间的前列腺癌新病例进行了回顾性分析。所有数据均借助SPSS 20.0软件进行分析。前列腺癌患者的平均年龄为68.34岁(标准差=8.559)。哈萨克斯坦政府在2017年投资了2043.7万坚戈(哈萨克斯坦坚戈),相当于61188美元,为一项对9638名男性进行检查的试点研究提供资金。2013年至2017年期间,在哈萨克斯坦巴甫洛达尔地区居住的49334名男性中,有1248名男性被诊断患有前列腺疾病,其中包括130例前列腺癌病例。前列腺癌的检出率为每月两例。在规定时间段内,该地区所有确诊的前列腺癌病例中,只有22.8%是通过政府资助的前列腺癌筛查项目发现的。在5年期间,巴甫洛达尔地区目标人群中的前列腺癌平均检出率为0.23%。鉴于前列腺癌筛查项目未能充分检测出新的前列腺癌病例,我们不建议继续进行此类筛查,除非对其进行仔细修订和重新规划。